Sushil Patel's most recent trade in Revolution Medicines Inc was a trade of 2,955 Common Stock done at an average price of $37.5 . Disclosure was reported to the exchange on June 29, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Revolution Medicines Inc | Sushil Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 37.54 per share. | 29 Jun 2026 | 2,955 | 27,236 (0%) | 0% | 37.5 | 110,931 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2026 | 2,955 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Sushil Patel | Director | Sale of securities on an exchange or to another person at price $ 185.90 per share. | 29 Jun 2026 | 1,100 | 24,936 (0%) | 0% | 185.9 | 204,489 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Sale of securities on an exchange or to another person at price $ 184.59 per share. | 29 Jun 2026 | 900 | 26,036 (0%) | 0% | 184.6 | 166,128 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Sale of securities on an exchange or to another person at price $ 192.61 per share. | 29 Jun 2026 | 881 | 21,656 (0%) | 0% | 192.6 | 169,693 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Sale of securities on an exchange or to another person at price $ 186.92 per share. | 29 Jun 2026 | 858 | 24,078 (0%) | 0% | 186.9 | 160,374 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Sale of securities on an exchange or to another person at price $ 190.54 per share. | 29 Jun 2026 | 600 | 23,078 (0%) | 0% | 190.5 | 114,327 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Sale of securities on an exchange or to another person at price $ 191.87 per share. | 29 Jun 2026 | 541 | 22,537 (0%) | 0% | 191.9 | 103,800 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Sale of securities on an exchange or to another person at price $ 187.83 per share. | 29 Jun 2026 | 300 | 23,778 (0%) | 0% | 187.8 | 56,348 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Sale of securities on an exchange or to another person at price $ 183.17 per share. | 29 Jun 2026 | 300 | 26,936 (0%) | 0% | 183.2 | 54,952 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Sale of securities on an exchange or to another person at price $ 188.57 per share. | 29 Jun 2026 | 100 | 23,678 (0%) | 0% | 188.6 | 18,857 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2026 | 3,127 | 3,127 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2026 | 1,191 | 24,281 (0%) | 0% | 0 | Common Stock | |
| Replimune Grp Inc | Sushil Patel | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 5.08 per share. | 18 May 2026 | 37,324 | 747,492 (2%) | 0% | 5.1 | 189,606 | Common Stock |
| Replimune Grp Inc | Sushil Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2026 | 376,860 | 376,860 | - | - | Employee Stock Option (right to buy) | |
| Replimune Grp Inc | Sushil Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2026 | 251,240 | 784,816 (2%) | 0% | 0 | Common Stock | |
| Plumas Bancorp. | Sushil A. Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2026 | 1,400 | 1,400 | - | - | Restricted stock units | |
| Replimune Grp Inc | Sushil Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2025 | 200,000 | 533,576 (1%) | 0% | 0 | Common Stock | |
| Replimune Grp Inc | Sushil Patel | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 11.13 per share. | 02 Dec 2025 | 10,000 | 333,576 (0%) | 0% | 11.1 | 111,300 | Common Stock |
| Plumas Bancorp. | Sushil A. Patel | Director | Purchase of securities on an exchange or from another person at price $ 41.31 per share. | 30 Jul 2025 | 650 | 3,685 (0%) | 0% | 41.3 | 26,852 | Common Stock |
| Plumas Bancorp. | Sushil A. Patel | Director | Purchase of securities on an exchange or from another person at price $ 41.00 per share. | 30 Jul 2025 | 649 | 3,035 (0%) | 0% | 41 | 26,609 | Common Stock |
| Plumas Bancorp. | Sushil A. Patel | Director | Purchase of securities on an exchange or from another person at price $ 41.00 per share. | 30 Jul 2025 | 1 | 2,386 (0%) | 0% | 41 | 41 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 11,574 | 11,574 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 3,142 | 23,090 (0%) | 0% | 0 | Common Stock | |
| Replimune Grp Inc | Sushil Patel | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.06 per share. | 20 May 2025 | 25,105 | 343,576 (0%) | 0% | 8.1 | 202,346 | Common Stock |
| Replimune Grp Inc | Sushil Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 250,000 | 250,000 | - | - | Employee Stock Option (right to buy) | |
| Replimune Grp Inc | Sushil Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 166,667 | 368,681 (1%) | 0% | 0 | Common Stock | |
| Plumas Bancorp. | Sushil A. Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 1,011 | 2,385 (0%) | 0% | - | Common Stock | |
| Plumas Bancorp. | Sushil A. Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 1,011 | 0 | - | - | Restricted stock units | |
| Replimune Grp Inc | Sushil Patel | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 12.42 per share. | 16 Dec 2024 | 10,000 | 202,014 (0%) | 0% | 12.4 | 124,200 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.84 per share. | 31 Oct 2024 | 5,000 | 24,948 (0%) | 0% | 24.8 | 124,200 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Sale of securities on an exchange or to another person at price $ 54.14 per share. | 31 Oct 2024 | 5,000 | 19,948 (0%) | 0% | 54.1 | 270,715 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 5,000 | 13,400 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Sushil Patel | Director | Sale of securities on an exchange or to another person at price $ 44.00 per share. | 09 Jul 2024 | 2,155 | 19,948 (0%) | 0% | 44 | 94,820 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2024 | 2,155 | 32,490 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Sushil Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.80 per share. | 09 Jul 2024 | 2,155 | 22,103 (0%) | 0% | 16.8 | 36,204 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 16,700 | 16,700 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 15,955 | 15,955 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 4,800 | 20,500 (0%) | 0% | 0 | Common Stock | |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 4,248 | 19,948 (0%) | 0% | 0 | Common Stock | |
| Plumas Bancorp. | Sushil A. Patel | Director | Purchase of securities on an exchange or from another person at price $ 35.65 per share. | 20 May 2024 | 1,126 | 1,226 (0%) | 0% | 35.7 | 40,142 | Common Stock |
| Plumas Bancorp. | Sushil A. Patel | Director | Purchase of securities on an exchange or from another person at price $ 35.49 per share. | 20 May 2024 | 100 | 100 (0%) | 0% | 35.5 | 3,549 | Common Stock |
| Plumas Bancorp. | Sushil A. Patel | Director | Purchase of securities on an exchange or from another person at price $ 35.64 per share. | 20 May 2024 | 50 | 1,374 (0%) | 0% | 35.6 | 1,782 | Common Stock |
| Plumas Bancorp. | Sushil A. Patel | Director | Purchase of securities on an exchange or from another person at price $ 35.50 per share. | 20 May 2024 | 50 | 1,276 (0%) | 0% | 35.5 | 1,775 | Common Stock |
| Plumas Bancorp. | Sushil A. Patel | Director | Purchase of securities on an exchange or from another person at price $ 35.56 per share. | 20 May 2024 | 48 | 1,324 (0%) | 0% | 35.6 | 1,707 | Common Stock |
| Replimune Grp Inc | Sushil Patel | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.47 per share. | 16 May 2024 | 20,194 | 212,014 (0%) | 0% | 6.5 | 130,655 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Sale of securities on an exchange or to another person at price $ 37.00 per share. | 10 Apr 2024 | 2,155 | 15,700 (0%) | 0% | 37 | 79,735 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2024 | 2,155 | 34,645 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Sushil Patel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.80 per share. | 10 Apr 2024 | 2,155 | 17,855 (0%) | 0% | 16.8 | 36,204 | Common Stock |
| Replimune Grp Inc | Sushil Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 250,000 | 250,000 | - | - | Employee Stock Option (right to buy) | |
| Replimune Grp Inc | Sushil Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 83,335 | 232,208 (0%) | 0% | 0 | Common Stock | |
| Plumas Bancorp. | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 1,011 | 0 | - | - | Restricted stock units | |
| Replimune Grp Inc | Sushil Patel | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 24.11 per share. | 13 Jun 2023 | 5,145 | 149,426 (0%) | 0% | 24.1 | 124,046 | Common Stock |
| Replimune Grp Inc | Sushil Patel | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 23.44 per share. | 13 Jun 2023 | 553 | 148,873 (0%) | 0% | 23.4 | 12,962 | Common Stock |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 18,400 | 18,400 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 5,200 | 15,700 (0%) | 0% | 0 | Common Stock | |
| Replimune Grp Inc | Sushil Patel | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 18.05 per share. | 16 May 2023 | 15,575 | 154,571 (0%) | 0% | 18.1 | 281,129 | Common Stock |
| Replimune Grp Inc | Sushil Patel | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 60,000 | 60,000 | - | - | Employee Stock Option (right to buy) | |
| Replimune Grp Inc | Sushil Patel | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 40,000 | 170,146 (0%) | 0% | 0 | Common Stock | |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 36,800 | 36,800 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Sushil Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 10,500 | 10,500 (0%) | 0% | 0 | Common Stock | |
| Replimune Grp Inc | Sushil Patel | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 14.59 per share. | 16 May 2022 | 10,687 | 130,146 (0%) | 0% | 14.6 | 155,923 | Common Stock |
| Replimune Grp Inc | Sushil Patel | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 78,750 | 78,750 | - | - | Employee Stock Option (right to buy) | |
| Replimune Grp Inc | Sushil Patel | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 52,500 | 140,833 (0%) | 0% | 0 | Common Stock |